Αρχική World News Clinical Trials in Genitourinary Cancers: MAGNITUDE, PROOF 302, and CYTOSHRINK

Clinical Trials in Genitourinary Cancers: MAGNITUDE, PROOF 302, and CYTOSHRINK

Clinical trials are the main way that doctors are able to find better treatment for diseases like cancer. Active clinical trials are exploring possible new cancer treatments and ways to prevent or reduce side effects. In this podcast series, members of the Cancer.Net Editorial Board share their expert opinions about ongoing clinical trials that are studying genitourinary (GU) cancers.

In this podcast, Timothy Gilligan, MD, FASCO, leads a discussion with Neeraj Agarwal, MD; Brian Shuch, MD; and Tian Zhang, MD, about 3 clinical trials in prostate cancer, bladder cancer, and kidney cancer.

Dr. Gilligan is a medical oncologist at the Cleveland Clinic Taussig Cancer Institute and a Cancer.Net Specialty Editor for Genitourinary Cancers. Dr. Agarwal directs the Genitourinary Oncology Program at the Huntsman Cancer Institute at the University of Utah and is a Cancer.Net Specialty Editor for Genitourinary Cancers. Dr. Shuch is the director of the Kidney Cancer Program at UCLA Health, the Alvin & Carrie Meinhardt Endowed Chair in Kidney Cancer Research at the institution, and a Cancer.Net Specialty Editor for Genitourinary Cancers. Dr. Zhang is an assistant professor of medicine at Duke University School of Medicine, a medical oncologist at Duke Cancer Institute, and a Cancer.Net Specialty Editor for Genitourinary Cancers.

Disclosure information for this podcast’s speakers can be found in their individual biographies, which are linked in the paragraph above.

Was this podcast useful? Please subscribe, rate, and review Cancer.Net Podcasts on Apple Podcasts or Google Play. This prerecorded podcast can be listened to online or downloaded to your computer. A transcript is also available. For more information, visit the Cancer.Net podcast page.

Cancer.Net podcasts are edited for length and content. 

Source

Προηγούμενο άρθροDress up that Salad!
Επόμενο άρθροHolidays, Traditions and Grief

NEWSLETTER

Συμπληρώστε το email σας για να λαμβάνετε τις σημαντικότερες ειδήσεις από το ogkologos.com

Βρείτε μας

2,449ΥποστηρικτέςΚάντε Like
57ΑκόλουθοιΑκολουθήστε

Διαβαστε Επίσης

ΕΞΕΛΙΞΕΙΣ ΣΤΗ ΘΕΡΑΠΕΙΑ ΤΟΥ ΜΗ-ΜΙΚΡΟΚΥΤΤΑΡΙΚΟΥ ΚΑΡΚΙΝΟΥ ΤΟΥ ΠΝΕΥΜΟΝΑ (ΜΜΚΠ)

ΕΞΕΛΙΞΕΙΣ ΣΤΗ ΘΕΡΑΠΕΙΑ ΤΟΥ ΜΗ-ΜΙΚΡΟΚΥΤΤΑΡΙΚΟΥ ΚΑΡΚΙΝΟΥ ΤΟΥ ΠΝΕΥΜΟΝΑ (ΜΜΚΠ) Γράφει ο Δρ Παπαδούρης Σάββας, Παθόλογος-Ογκολόγος   Ο ΜΜΚΠ βρίσκεται αναλογικά στο 80% και πλέον του συνολικού...

Διατρέχουν όντως οι καρκινοπαθείς μεγαλύτερο κίνδυνο λόγω κοροναϊού;

Σε πρακτικό επίπεδο, τα δεδομένα των σχετικών μελετών υποδηλώνουν ότι η χημειοθεραπεία ή οι άλλες αντι-νεοπλασματικές θεραπείες δεν αυξάνουν σημαντικά τον κίνδυνο θνησιμότητας από...

FDA: Η ακτινοβολία των smartphones δεν προκαλεί καρκίνο

Σε μια νέα έκθεσή της, η Υπηρεσία Τροφίμων και Φαρμάκων (FDA) των ΗΠΑ αναφέρει ότι επανεξέτασε τις σχετικές επιστημονικές έρευνες που δημοσιεύθηκαν τα τελευταία...

Νέα ανακάλυψη, νέα ελπίδα για τον καρκίνο

Ένα νεοανακαλυφθέν τμήμα του ανοσοποιητικού μας συστήματος θα μπορούσε να αξιοποιηθεί για την αντιμετώπιση όλων των ειδών καρκίνου, σύμφωνα με επιστήμονες του πανεπιστημίου Cardiff...

Καρκίνος: Ευεργετική για τους καρκινοπαθείς η άσκηση

Σημαντικά ωφέλη προσφέρει η άσκηση, ακόμη και σε ασθενείς με καρκίνο. Οι περισσότεροι ασθενείς αγνοούν τα οφέλη που μπορεί να έχει γι’ αυτούς η συχνή...

Prostate Cancer

The article is provided by Scientific Communications Officer of NIPD Genetics, Ms Marina Charitou (MSc) Prostate Cancer Awareness Prostate cancer is the second most common cancer...
- Advertisment -

Ροή Ειδήσεων

Discovering the BRCA2 gene – 25 years on

A breast cancer cell. Credit: LRI EM Unit. 25 years ago, a team of our scientists were celebrating. Their risky strategy had paid off. “You...

Newly Developed RSClin Provides Prognostic Information in HR-positive, HER2-negative Early Breast Cancer

The online RSClin tool incorporating clinical-pathological data and the results of a 21-gene recurrence score (RS) was able to estimate the risk of distant...

Embracing Bravery When You Have a Genetic Cancer Disease

Emily Pinto Billcheck is a licensed social worker with experience in the mental health field. She is a von Hippel-Lindau (VHL) patient who inherited VHL from her...

Chemotherapy Administered for the First Diagnosed Testicular Cancer Reduces the Risk of Metachronous Contralateral Testicular Cancer Occurrence

Patients aged less than 30 years upon diagnosis of testicular cancer and those treated with surgery only are at higher risk of developing a...

New Research Looks for More Effective Breast Cancer Treatments for Black Women

Breast cancer affects people across all different backgrounds, but Black women in particular are more apt to get aggressive forms of the disease. They’re...

Palbociclib Plus Endocrine Therapy Does Not Improve PFS over Capecitabine in HR-positive, HER2-negative Aromatase Inhibitor Resistant Metastatic Breast Cancer

Although patients with hormone receptor (HR)-positive and human epidermal growth factor receptor 2 (HER2)-negative, aromatase inhibitor resistant metastatic breast cancer maintained quality of life...